INTRODUCTION
Treatment strategies for patients with acute myeloid leukemia (AML) are based on various prognostic factors including age and performance status of the patient, as well as cytogenetic and molecular characteristics of the leukemic clone. Key objectives in predicting the prognosis of AML are on the one hand, to define patients with high risk of relapse in order to apply more intensive therapy such as allogeneic stem cell transplantation, on the other hand to withhold aggressive therapy when final success seems highly unlikely. 1 Hematological malignancies are developed and maintained not only by the molecular events inside the malignant cell clone but also by their interaction with the microenvironment. The crosstalk between stroma and malignant cells has a major impact on pathophysiological behaviour and progress of the disease. [2] [3] [4] Osteopontin (OPN) is a secreted glycoprotein of the SIBLING-family and is involved in physiologic and pathophysiologic processes. 5 Its different effects are due to its multiple receptors and isoforms. Cleavage of osteopontin leads to molecular mass facilitating binding to various receptors like CD44, α9β1, and α4β7. 5 In vitro, OPN has been shown to influence adhesion and migration of smooth muscle cells, endothelial cells and melanoma cells. 5 OPN exerts dual functions as a chemoattractant cytokine and as an extracellular component. 5 Previous studies indicated a role for osteopontin in several malignancies. While most of the publications so far focused on solid cancers 6, 7 , there had been recent advances in deciphering the role of OPN in hematological malignancies. [8] [9] [10] It has been shown that OPN contributes to bone-marrow adhesion and migration of hematopoietic stem cells (HSC). 11 OPN may act as a negative regulator of the HSC through the inhibition of HSC division. 11 HSC-adhesion to osteoblasts leads to a resting state of the HSC in the stem cell niche with protection from cytotoxic and apoptotic stimuli. 12 Here, we analyzed expression of OPN in bone-marrow, AML-blasts and serum of AML-patients. We demonstrate that the expression of OPN is increased on the mRNA and protein level in AML-patients compared to healthy controls. OPN emerged as an independent prognostic marker in AML.
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PATIENTS AND METHODS

Patient characteristics
Immunohistochemical analysis (IH) cohort: Bone-marrow sections of 84 patients with newly diagnosed, untreated AML were randomly chosen. Three controls were taken from patients with various diseases but normal bone-marrow morphology. Bone-marrow core-biopsies were obtained at presentation. After core biopsy a bone-marrow aspiration was obtained through a separate puncture for cytological analysis. All patients were treated uniformly according to the German-AML-cooperative-group (AMLCG) trial as published in detail. 13, 14 All patients gave their informed consent in accordance with the Declaration of Helsinki and the study received approval from the local ethics comittees of the participating institutions. Patient characteristics are summarized in Table 1 . Immunohistochemical expression: OPN-expression was semiquantitatively assessed by scoring the proportion and intensity of stained cells according to our published methods. 19 The entire bone-marrow section was scanned at low 
Enzyme-linked immunosorbent assays (ELISA)
ELISA were performed using available kits from R&D-Systems (Minneapolis,USA). Briefly, patient samples were collected using EDTA and stored at -80°C. Serum samples were added to separate microplates, each containing specific antibody. Mixtures were incubated at room temperature.
Plates were washed to remove unbound antigen. Enzyme-linked antibodies specific for OPN were then added and the mixtures were incubated followed by washing steps. The substrate solution was added to the wells. Color
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Statistics
Beyond descriptive statistical analyses, inferential analyses were performed using non-parametric methods. Differences in OPN expression between 2 groups were analyzed using the Mann-Whitney-U-test for independent groups. In the case of more than 2 groups the Kruskal-Wallis test was used. Correlation between metric variables was assessed by the Spearman-rank-correlationcoefficient (r s ). End points were defined as published. 20 Patients who survived the entire follow-up period were censored at the date of last contact. Cut-off values of OPN-levels were determined by recursive partitioning. In addition, Bootstrap analysis and hazard ratio per unit were determined to identify the stability of the identified cut-off points. Survival curves were generated using the Kaplan-Meier method and the log-rank test was used to compare survival between groups.
Univariate and multivariate Cox proportional hazards-regression analyses were performed to evaluate the impact of prognostic factors on survival. Factors found to be statistically significant at a 10%-level in the univariate analyses were included in the multivariate model. Two-sided p-values ≤ 0.05 were considered to indicate significant differences. All calculations were performed using the SPSSsoftware (SPSSInc.,Chicago,IL,USA).
RESULTS
Immunohistochemical analysis
Expression of OPN was analyzed by immunohistochemical staining in bonemarrow core biopsies of 84 AML-patients. The patients' characteristics are presented in Table 1 . In AML and control patients, staining intensity varied from We analyzed the association between pretherapeutic OPN-expression and prognosis in AML ( Figure 1C,D) . Optimized cut-off points were identified by recursive partitioning, and an AU=9.662 was defined as cut-off. 20 18.2% of the analyzed AML-patients had an OPN-expression level above that cut-off value.
Univariate analysis revealed that patients expressing high levels of OPN (AU>9.662) in the bone-marrow had significantly shorter OS than those with low OPN-levels (p=0.025). The median survival time of high OPN-expressing AMLpatients was more than 2-fold longer than survival time of patients with low OPNexpression (3.7 vs. 1.5 years). Figure 1 Figure 1D ), although this correlation failed to reach the level of significance (p=0.279). This is most likely explained by the lower number of patients available for this analysis.
For
OPN-levels in patients` serum
Levels of OPN were analyzed in pretherapeutic bone-marrow and blood serum samples of patients with AML and healthy individuals ( Table 1 To determine the relationship of OPN-protein expression levels and prognosis in AML, we performed univariate Cox-proportional hazard analyses. As expected, the variables karyotype (favorable vs. intermediate/unfavourable), WBC and LDH displayed prognostic significance. Furthermore, using the dichotomous cut-off levels identified by recursive partitioning, OPN-protein expression in the bonemarrow was significantly associated with survival (Figure 2A,B) . Blood OPNlevels showed no prognostic significance (data not shown). OS and EFS were significantly lower for patients with bone-marrow OPN-levels above 6.32ng/ml in the marrow serum. Figure 3 indicates the Kaplan-Meier curves of OS and EFS stratified for OPN-levels. An association was detected between high levels of OPN-expression and therapy resistance to induction therapy (p=0.009). We could only speculate that OPN may act already at that early timepoint as a negative regulator of leukemic cell proliferation and thus chemotherapy resistance. This prompted us to investigate whether OPN-expression levels at diagnosis would influence outcome even after an initial remission was reached.
The analysis was restricted to patients that achieved a complete remission after induction chemotherapy. Nonetheless, OPN-expression levels at diagnosis showed a significant and independent impact on survival ( Figure 3C ; p=0.016).
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In the patient group who died in CR (n=36) the numbers were too low for statistical analysis. Only 9 patients were in the high OPN-group. In addition, we analysed whether OS and EFS were altered by exclusion of AML-M3 patients, who have a higher expression of OPN in contrast to the other FAB-types. The significance value for OS is not altered, whereas, as expected, the EFS was even more significant. The p-value changed from 0.0002 to 0.00003. For patients who reached a complete remission, high OPN-expression was still significant in terms of EFS (p=0.006). We subsequently investigated if OPN presents a prognostic factor in the different cytogenetic risk groups. Interestingly, OPN remained a significant prognostic factor in intermediate risk patients (Figure 3D ; p=0.045).
Validation of cut-off values and Hazard Ratio per unit increase in OPN
In order to validate the determined optimal cut-off values of OPN-levels a bootstrap approach was applied. The 1000-bootstrap-samples results showed weak reproducibility. (Suppl. Table: 2). This finding indicates that the cutpoints used in our analyses should not be regarded as the best that can be achieved in different experiments. Rather, the findings indicate that rising OPN-levels indicate increased risk for therapy failure. In all three analyses OPN-levels showed a unfavorable hazard ratio per unit increase in OPN that reaches significance in case of mRNA OPN (Suppl. Table: 3).
DISCUSSION
In this retrospective study, we identified osteopontin expression as analyzed on the mRNA and protein level as a prognostic marker in AML. In three different patient cohorts and with various methods we demonstrate that increased expression of OPN was associated with shortened survival. While in control bone-marrow, OPN was only expressed by osteoblasts within the endosteal region, we could demonstrate OPN is readily expressed in AML blasts. The analyses (cut-off value defined by statistical optimization) revealed that OPN is highly expressed in approximately 20% of AML (ELISA:23%; IH:18%, RNA:23%) and is neither asscociated with FAB-type, nor with cytogenetic or molecular alterations. In addition, in a recently published dataset from the Mile-study we also identified significantly increased levels of OPN in AML compared to normal bone-marrow (data not shown). 21 Several studies indicated a role for OPN in different malignancies. While most of the publications had focused on solid cancers, 6, 7 there have been recent advances in deciphering the role of OPN in hematological malignancies. [8] [9] [10] Increased serum OPN-concentrations have been reported in chronic myeloid leukemias, multiple myelomas and AML. 22 Lee et al.
demonstrated in a small cohort that marrow levels of higher OPN is associated with a significant shorter survival in AML-patients in a 1-year survival analysis,
while 5-year analysis revealed no statistical difference. 7 Powell et al. 23 performed expression screen to identify targets in AML. These analyses identified OPN as a functionally relevant target. siRNA-mediated knockdown of OPN-expression induced cell death in both AML blasts and leukemic progenitors. These authors could demonstrate that in normal karyotype AML, increased expression of OPN at diagnosis is associated with poor prognosis (n=60). 23 The important function of OPN in normal hematopoiesis appears to be the suppression of proliferation of primitive stem cells in the bone-marrow niche, as evidenced with OPN-/-mice and in-vitro colony formation assays. 11, 24 These data therefore provide strong evidence that OPN is an important component of the HSC-niche participating in HSC-location and as a physiologically negative regulator of HSC-proliferation.
11
Furthermore, exogenous OPN suppresses the proliferation of primitive HSC in vitro. The relevance of this observation is demonstrated by the markedly enhanced cycling of HSC in OPN-/-mice 11 and their hypersensitivity to exogenous stimuli. 24, 25 Considering these biologic effects of OPN and the significant influence of OPN-expression on prognosis as measured by EFS and OS in our study, we assume that OPN contributes to chemotherapy resistance in a paracrine/autocrine manner.
The self renewal of leukemic stem cells (LSC) may have an extrinsic component like OPN, as it is known for normal HSC. 24 The importance of the leukemic stem cell mircoenviroment has also been demonstrated. 26 Their data indicated that mesenchymal stem cells are essential for the long-term survival and expansion of 
Kaplan-Meier curves for overall survival (OS, A) and event free survival (EFS, B)
of AML patients stratified for bone-marrow serum OPN expression. OS of patients with low (<6.632 ng/ml) levels of OPN in the bone-marrow was significantly higher than in patients with high (≥ 6.632 ng/ml) OPN expression (A, p=0.018). Similar differences were found for EFS (B, p=0.008). 
